Acetaminophen Market Poised for Growth, Projected to Reach USD 15.2 Billion by 2033 at a 4.2% of CAGR

Acetaminophen
Acetaminophen Market

The acetaminophen market is experiencing significant growth, boasting a valuation of USD 9.8 billion by the end of 2022. According to a recent study by Future Market Insights, the market is set to expand at a CAGR of 4.2%, reaching an impressive USD 15.2 billion by 2033.

Acetaminophen, widely recognized for its efficacy in pain relief and fever reduction, continues to be a staple in households and healthcare settings globally. The recent study highlights that the oral route of administration dominates the market, accounting for a remarkable 92.4% share in 2022. This preference underscores the convenience and widespread acceptance of oral acetaminophen among consumers and healthcare providers alike.

The projected growth of the acetaminophen market reflects the increasing demand for over-the-counter pain relievers and fever reducers. As the global population continues to grow and age, the need for effective and accessible pain management solutions becomes even more critical.

Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14325

Global Health Issues:

The field of pain management is intricately linked to worldwide health issues, particularly the profound effects of cancer. Given that 19.3 million people would be impacted by cancer globally in 2020, the National Cancer Institute’s finding that 20% to 50% of cancer patients experience pain highlights how important efficient analgesics are. The aging population is expected to add 21.7 million more cancer cases globally by 2030, increasing the need for trustworthy pain management treatments.

After-Opioid Epidemic Transition:

In the aftermath of the USA opioid epidemic, nations worldwide are recalibrating their approach to opioid prescribing. Governments in industrialized nations are championing the adoption of non-opioid analgesics, presenting a unique opportunity for businesses to pioneer cutting-edge non-opioid medications.

Key Takeaways:

  • Based on product type, the acetaminophen segment is projected to growt at a 4.1% CAGR through 2031.
  • The oral route of administration segment accounted for 92.4% of the total market share in 2021.
  • In terms of sales type, the OTC (over the counter) segment accounted for 91.6% of the global market share in 2021.
  • Sales through retail pharmacies will continue gaining traction. In 2021, the segment accounted for 28.5% of the total market share.
  • North America held the largest share of 33.0% of the global acetaminophen market in 2021, and the trend is expected to continue over the assessment period.

“Growing demand for self-aid and cost-effective OTC pain relievers, along with increasing usage of acetaminophen as the first line of treatment for pain management are the key factors projected to drive the market in the forthcoming years,” says the FMI analyst.

Competition Landscape:

Leading players operating in the global acetaminophen market are Abbott, Janssen Pharmaceuticals, Inc. [Johnson & Johnson], Bristol-Myers Squibb and Company, Cardinal Health Inc., Viatris, Procter & Gamble Company, Sanofi, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Perrigo Company, Mallinckrodt Pharmaceuticals, Glaxo SmithKline Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.

Some of the leading companies of the acetaminophen market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence. For instance:

  • Johnson & Johnson, In March 2020,  announced that it will be boosting up production of its flagship product Tylenol which is an over-the-counter pain killer
  • GlaxoSmithKline, In February 2020 was approval by the Food and Drug Administration for Advil Dual Action, with acetaminophen as an over-the-counter (OTC) product for pain relief.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-14325

Key Companies Profiled:

  • Pfizer Inc.
  • Sanofi
  • Janssen Pharmaceuticals.
  • Bayer AG
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb and Company
  • Teva Pharmaceutical Industries Ltd
  • Cardinal Health Inc.
  • Perrigo Company.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Abbott
  • Mallinckrodt Pharmaceuticals
  • Procter & Gamble Company

Key Market Segments Covered in Acetaminophen Drugs Industry Research:

By Product:

  • Acetaminophen
  • Acetaminophen with Opioids
  • Others

By Route of Administration:

  • Oral
  • Injectable
  • Others

By Sales:

  • OTC (Over-the-counter)
  • Rx (Prescription)

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-commerce
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

In-Depth Market Overview: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/14325

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *